Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04807439 · ClinicalTrials.gov registry record
A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 100
- Enrollment target
NCT04807439 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 100 participants.
The verdict
NCT04807439 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in length (by visual estimate) in native coronary arteries ≥3.50 mm to ≤5.00 mm in diameter (by visual estimate). This Post Approval study is a cohort associated with the Evolve 4.5/5.0 (SYNERGY LV) Post Approval Study, which is registered under ClinicalTrials.gov ID: NCT03875651.
Interventions
- DEVICE SYNERGY XLV (Megatron) Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2023-08-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04807439
The ClinicalTrials.gov registry entry for NCT04807439 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SYNERGY XLV (Megatron) Coronary Stent System is the first listed.
NCT04807439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04807439 about?
NCT04807439 is a clinical study titled "A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System". This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in length (by visual estimate) in native coronary arteries ≥3.50 mm to ≤5.0...
What is the current status of trial NCT04807439?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2021-04-14. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT04807439?
The interventions under investigation include: SYNERGY XLV (Megatron) Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT04807439?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.